Galactose Cataract Prevention with Sorbinil, an Aldose Reductase Inhibitor: a Light Microscopic Study

Total Page:16

File Type:pdf, Size:1020Kb

Galactose Cataract Prevention with Sorbinil, an Aldose Reductase Inhibitor: a Light Microscopic Study Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study M. Datiles, H. Fukui, T. Kuwabara, andj. H. Kinoshita Cataract formation in galactosemic rats was studied by ophthalmoscopy, slit-lamp biomicros- copy, and by light microscopy using plastic embedding with methacrylate. Untreated rats developed nuclear cataracts by 14 days and mature cataracts by 21 days. However, rats treated with the aldose reductase inhibitor sorbinil did not develop any cataractous change for up to 8 months of 50% galactose feeding and could not be distinguished from normal controls. This strongly suggests that aldose reductase is the common factor involved in the formation of sugar cataracts. (INVEST OPHTHALMOL VIS SCI 22:174-179, 1982.) Key words: galactosemic cataract, aldose reductase inhibitor, methacrylate plastic embedding Aildos, e reductase (AR) has been implicated Methods as the common factor which initiates the cata- Male Sprague-Dawley albino rats weighing 50 ractous process in both diabetic and galac- gin were fed 50% galactose feed. Rats were treated tosemic rats.1 A variety of AR inhibitors with with sorbinil given by oral intubation at a dose of diverse chemical structures has been shown 60 mg/day/kg body weight. Subsequent experi- to effectively delay the onset of cataracts in ments showed that the same results were obtained diabetic and galactosemic animals.2"6 More- when the sorbinil was mixed with rat feed (425 mg/kg of food). A total of 250 rats in each of the over, the inhibitor sorbinil (d-6-fluorospiro- untreated and sorbinil-treated groups were used. chroman 4,4'imidazolidine 2',5'dione) has The eyes were examined daily with pupils di- recently been reported to essentially prevent lated by a cycloplegic-mydriatic (0.5% to 1.0% cy- cataractous changes from occurring in dia- clopentolate (Cyclogyl); Alcon Laboratories, Inc., 6 betic rats. To complete documentation on Ft. Worth, Texas), and the lenses were examined the treatment of sugar cataracts with AR in- with an American Optical direct ophthalmoscope hibitors, we present a light microscopic study and an American Optical slit-lamp Biomicroscope. of the lenses of galactosemic rats treated with For histology, samples were taken at 3, 7, 10, 14 sorbinil. and 21 days. The rats were sacrificed with an overdose of sodium pentobarbital; the eyes were carefully enucleated and then fixed overnight in 4% glutar- aldehyde in 0.15M sodium-potassium phosphate buffer, pH 7.2. The eyes were slit open at the From the Laboratory of Vision Research, National Eye limbus 10 min after start of fixation to allow the Institute, National Institutes of Health, Bethesda, Md. rapid entry of the fixative. The eyes were trans- Submitted for publication Jan. 30, 1981. ferred to 10% buffered formaldehyde the next day Reprint requests: Jin H. Kinoshita, Laboratory of Vision and further fixed for several days. They were then Research, Bldg. 6, Room 222, National Eye Institute, dehydrated for 2 hr each in a series of ethyl al- 9000 Rockville Pike, Bethesda, Md. 20205. cohols (50%, 70%, 80%, 90%, and 95%) and 174 Downloaded from iovs.arvojournals.org on 10/01/2021 Volume 22 Number 2 Galactose cataract prevention with sorbinil 175 infiltrated with three changes of plastic (methacry- late) embedding mixture, solution A with catalyst (JB-4 embedding kit; Polysciences Inc.) at 2 hr intervals. A final embedding mixture, 20 to 25:1 ratios of solution A with catalyst and solution B, was poured into plastic molds. The well-infiltrated whole eyes were then dropped into the molds and positioned, and the medium allowed to harden. Within 30 to 45 min, the medium had poly- merized sufficiently hard to allow an oily residue to be washed off the surface with soapy water. The molds were then left overnight to harden, and the block was cut the next day on a Sorvall JB-4A mi- crotome. Sections 1 to 2.5 fim thick were cut with a Vi-inch thick glass knife. The sections were floated on water, mounted on a glass slide, dried on a hot plate, and stained (hematoxylin/eosin, periodic acid-Schiff stain (PAS), or toluidine blue). They were then covered with a cover slip, Fig. 1. Gross photograph of mature galactosemic examined, and photographed with a Carl Zeiss mi- cataract in the rat. croscope. Samples were also processed by Ameri- can Histolabs (Rockville, Md.). In the histological studies we found that the equator at the third day on the galactose diet. plastic-embedding method, a procedure not widely All rats developed a nuclear opacity that was used for the lens, yielded results far superior to grossly visible by 2 weeks and had mature that of the paraffin-embedding technique. The cataracts by day 21 (Fig. 1). In striking con- whole eye was routinely embedded as in the paraf- trast, all rats treated with sorbinil showed no fin procedure. This avoids introducing artifacts lens changes when examined by the oph- caused in dissecting out the fresh lens. Moreover, with the plastic method it is possible to section the thalmoscope or slit lamp Biomicroscope al- eye so as to obtain sections as thin as 1 /xm. The though they had been maintained on the 50% water-iniscible plastic rapidly infiltrates and is not galactose diet for up to 8 months. The affected by high humidity. Furthermore, the sorbinil-treated rats were examined daily for simple procedure does not require ultraviolet the first month on the galactose diet and irradiation. Routine staining methods used for weekly thereafter. These lenses could not be paraffin are also applicable to the plastic fixed ma- distinguished from the normal control rat terial. lenses. Sorbinil effectively blocked the syn- The simple method allows for a magnification of thesis of galactitol, so that the level of polyol up to 1000X with light microscopy, gives excellent accumulation in the lenses were less than definition of cataractous changes, and is relatively 10% of those in the untreated galactosemic free of artifacts. When many cataracts are being rats. examined, the use of the relatively thin section of plastic-embedded specimens is the procedure of Histological changes of the lenses choice. When greater definitions of a particular Untreated, galactose-fed rats area of the cataract is required, electron micros- INITIAL VACUOLAR STAGE. Three days after copy can be employed. initiation of the 50% galactose feed, the lenses of all rats showed pre-equatorial and Results equatorial vacuoles {Fig. 2). These were de- Ophthalmoscopic and slit lamp observa- scribed previously as located between fibers tions. Cataracts in the galactose-fed rats and were called intercellular cysts.7 The lens progressed almost at the same rate in all ani- fibers were swollen, and those in the bow mals, and the dense nuclear opacity formed area appeared particularly vulnerable. usually 14 days after the start of the diet. The INTERMEDIATE VACUOLAR STAGE. Seven days first obvious change were vacuoles at the after the start of the galactose diet, the swell- Downloaded from iovs.arvojournals.org on 10/01/2021 176 Datiles et al. Invest. Ophthalmol. Vis. Sci. February 1982 Figs. 2 to 6. For legends see facing page. Downloaded from iovs.arvojournals.org on 10/01/2021 Volume 22 Number 2 Galactose cataract prevention with sorbinil 111 ing of the lens fibers and formation of vacu- cells continued to proliferate and form multi- oles were prominent in the anterior and layers of cells. The nucleus was displaced. posterior cortical area. In some areas, there The deep lens fibers were disintegrating. was already liquefaction of cortical lens fi- Sorbinil-treated galactose-fed rats. Close bers. Abnormal local proliferation of anterior histological examinations of the lenses of the lens epithelial cells was also observed (Fig. sorbinil-treated rats fed galactose for 3, 7, 10, 3). These abnormally proliferating cells con- 14, and 21 days revealed no change, and such tinued to produce basement membrane in a lenses could not be distinguished from nor- disorderly fashion. mal control rat lenses. Changes seen in the LATE VACUOLAR STAGE. There was further untreated group could not be detected in the liquefaction of the cortical lens fibers as well treated group. as proliferation of anterior epithelial cells at Similarly, histological examination of the 10 days. The anterior and posterior Y sutures lenses of rats fed galactose and treated with were seen with gaping spaces, and the gaps sorbinil for 1, 3, 6, and 8 months revealed no were filled with what appeared to be lique- cataractous changes, and such lenses could fied cortical material. The supranuclear lens not be distinguished from normal control rat fibers were swollen, and the ends of the lenses (Fig. 6). fibers appeared to have swollen many times the normal size (Fig. 4). The cells in the bow Discussion area were also edematous. Cataracts that can be induced in galac- NUCLEAR CATARACT STAGE. At 14 days, the tosemic rats occur much more readily than in cortex was mainly liquefied. The bow area diabetic rats. Early lens changes detectable still showed actual formation of new lens fiber in lenses of rats fed galactose for only 3 days cells. Extensive liquefaction occurred in the require 2 to 3 weeks to occur in diabetic rats. area of the Y sutures. The lens epithelial cells A dense nuclear opacity in galactose-fed rats showed foci of proliferation and evidence of occurs in 2 weeks, whereas in diabetic rats it multilayering of cells. The lens nucleus was appears in 9 to 12 weeks.8"12 noted to be floating in the fluid cortex. Sugar level obviously is an important fac- MATURE CATARACT STAGE. At 21 days, the cor- tor. However, the difference in the rate of tex, as already seen on day 14, was liquefied cataract formation between the galactose and (Fig.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Upregulations of Clcn3 and P-Gp Provoked by Lens Osmotic Expansion in Rat Galactosemic Cataract
    Hindawi Journal of Diabetes Research Volume 2017, Article ID 3472735, 8 pages https://doi.org/10.1155/2017/3472735 Research Article Upregulations of Clcn3 and P-Gp Provoked by Lens Osmotic Expansion in Rat Galactosemic Cataract 1 2 1 Lixia Ji, Lixia Cheng, and Zhihong Yang 1Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China 2Department of Endocrinology, People’s Hospital of Weifang, Weifang, China Correspondence should be addressed to Lixia Ji; [email protected] Received 21 September 2017; Accepted 1 November 2017; Published 21 November 2017 Academic Editor: Hiroshi Okamoto Copyright © 2017 Lixia Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Lens osmotic expansion, provoked by overactivated aldose reductase (AR), is the most essential event of sugar cataract. Chloride channel 3 (Clcn3) is a volume-sensitive channel, mainly participating in the regulation of cell fundamental volume, and P-glycoprotein (P-gp) acts as its modulator. We aim to study whether P-gp and Clcn3 are involved in lens osmotic expansion of galactosemic cataract. Methods and Results. In vitro, lens epithelial cells (LECs) were primarily cultured in gradient galactose medium (10–60 mM), more and more vacuoles appeared in LEC cytoplasm, and mRNA and protein levels of AR, P-gp, and Clcn3 were synchronously upregulated along with the increase of galactose concentration. In vivo, we focused on the early stage of rat galactosemic cataract, amount of vacuoles arose from equatorial area and scattered to the whole anterior capsule of lenses from the 3rd day to the 9th day, and mRNA and protein levels of P-gp and Clcn3 reached the peak around the 9th or 12th day.
    [Show full text]
  • Sudheendran-Dissertation
    © Copyright by Narendran Sudheendran 2013 All Rights Reserved STUDYING MOUSE EMBRYONIC DEVELOPMENT WITH OCT A Dissertation Presented to the Faculty of the Department of Biomedical Engineering University of Houston In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Biomedical Engineering by Narendran Sudheendran December 2013 STUDYING MOUSE EMBRYONIC DEVELOPMENT WITH OCT ___________________________ Narendran Sudheendran Approved: ________________________________ Chair of the Committee Kirill V. Larin, Associate Professor, Department of Biomedical Engineering Committee Members: ________________________________ Irina V. Larina, Assistant Professor, Department of Molecular Physiology and Biophysics, Baylor College of Medicine ________________________________ Rajesh C. Miranda, Associate Professor, Department of Neuroscience and Experimental Therapeutics, TAMHSC College of Medicine _______________________________ Howard Gifford, Associate Professor, Department of Biomedical Engineering _______________________________ Yingchun Zhang, Assistant Professor, Department of Biomedical Engineering ____________________________ _______________________________ Suresh K. Khator, Associate Dean, Metin Akay, Professor and Chairman, Cullen College of Engineering Department of Biomedical Engineering ACKNOWLEDGEMENTS I am extremely thankful to my advisor, Dr. Kirill Larin, for his guidance, support and encouragement throughout this work. I am extremely grateful to Dr. Irina Larina for her time and effort to help me during the entire course of my project. I would especially like to thank Saba, Maleeha, Dr. Shameena Bake and Chen for helping me with the experiments. I thank Esteban, Shang and Manmohan for reviewing my dissertation. I am thankful to Mohamad, Kiran, Venu, Stepan, Jiasong, Peter and the rest of the BOL team for their support and encouragement. I would like to thank Dr. Rajesh C. Miranda and Dr. Howard Gifford and Dr. Yingchun Zhang for their time to serve on my defense committee.
    [Show full text]
  • Dismetabolic Cataracts
    ndrom Sy es tic & e G n e e n G e f T o Journal of Genetic Syndromes Cavallini et al., J Genet Syndr Gene Ther 2013, 4:7 h l e a r n a r p u DOI: 10.4172/2157-7412.1000165 y o J & Gene Therapy ISSN: 2157-7412 Case Report Open Access Dismetabolic Cataracts: Clinicopathologic Overview and Surgical Management with B-MICS Technique Cavallini GM1, Forlini M1, Masini C1, Campi L1, Chiesi C1, Rejdak R2 and Forlini C3* 1Institute of Ophthalmology, University of Modena, Modena, Italy 2Department of Ophthalmology, Medical University of Lublin, Lublin, Poland 3Department of Ophthalmology, “Santa Maria Delle Croci” Hospital, Ravenna, Italy Abstract Background: Dismetabolic cataract is a loss of lens transparency due to an insult to the nuclear or lenticular fibers, caused by a metabolic disorder. The lens opacification may occur early or later in life, and may be isolated or associated to particular syndromes. We describe some of these metabolic conditions associated with cataract formation, and in particular we report our experience with a patient affected by lathosterolosis that presented bilateral cataracts. Methods: Our patient was a 7-years-old little girl diagnosed with lathosterolosis at age 2 years, through gas cromatography/mass spectrometry method for plasma sterol profile that revealed a peak corresponding to cholest- 7-en-3β-ol (lathosterol). Results: The lens samples obtained during surgical removal with B-MICS technique were sent to the Department of Pathology and routinely processed and stained with haematoxylin-eosin and PAS; then, they were examined under a light microscope. Histological examination revealed lens fragments with the presence of fibers disposed in a honeycomb way, samples characterized by the presence of homogeneous eosinophilic lens fibers, and other fragments characterized by bulgy elements referable to cortical fibers with degenerative characteristics.
    [Show full text]
  • Textbook of Ophthalmology, 5Th Edition
    Textbook of Ophthalmology Textbook of Ophthalmology 5th Edition HV Nema Former Professor and Head Department of Ophthalmology Institute of Medical Sciences Banaras Hindu University Varanasi India Nitin Nema MS Dip NB Assistant Professor Department of Ophthalmology Sri Aurobindo Institute of Medical Sciences Indore India ® JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD. New Delhi • Ahmedabad • Bengaluru • Chennai Hyderabad • Kochi • Kolkata • Lucknow • Mumbai • Nagpur Published by Jitendar P Vij Jaypee Brothers Medical Publishers (P) Ltd B-3 EMCA House, 23/23B Ansari Road, Daryaganj, New Delhi 110 002 I ndia Phones: +91-11-23272143, +91-11-23272703, +91-11-23282021, +91-11-23245672 Rel: +91-11-32558559 Fax: +91-11-23276490 +91-11-23245683 e-mail: [email protected], Visit our website: www.jaypeebrothers.com Branches 2/B, Akruti Society, Jodhpur Gam Road Satellite Ahmedabad 380 015, Phones: +91-79-26926233, Rel: +91-79-32988717 Fax: +91-79-26927094, e-mail: [email protected] 202 Batavia Chambers, 8 Kumara Krupa Road, Kumara Park East Bengaluru 560 001, Phones: +91-80-22285971, +91-80-22382956, 91-80-22372664 Rel: +91-80-32714073, Fax: +91-80-22281761 e-mail: [email protected] 282 IIIrd Floor, Khaleel Shirazi Estate, Fountain Plaza, Pantheon Road Chennai 600 008, Phones: +91-44-28193265, +91-44-28194897 Rel: +91-44-32972089, Fax: +91-44-28193231, e-mail: [email protected] 4-2-1067/1-3, 1st Floor, Balaji Building, Ramkote Cross Road Hyderabad 500 095, Phones: +91-40-66610020, +91-40-24758498 Rel:+91-40-32940929 Fax:+91-40-24758499, e-mail: [email protected] No. 41/3098, B & B1, Kuruvi Building, St.
    [Show full text]
  • In Vitro Anticataract Activity of Tamarindus Indica Linn. Againest Glucose-Induced Cataractogenisis
    Results IN VITRO ANTICATARACT ACTIVITY OF TAMARINDUS INDICA LINN. AGAINEST GLUCOSE-INDUCED CATARACTOGENISIS Dissertation submitted to The Tamil Nadu Dr. M. G. R. Medical University, Chennai in partial fulfillment of the award of degree of MASTER OF PHARMACY (PHARMACOLOGY) Submitted by SRIKANTH MERUGU Under the guidance of Mrs. M. UMA MAHESWARI, M. Pharm., (Ph.D.,) Assistant Professor, Department of Pharmacology MARCH – 2009 COLLEGE OF PHARMACY SRI RAMAKRISHNA INSTITUTE OF PARAMEDICAL SCIENCES COIMBATORE – 641 044. 1 Results IN VITRO ANTICATARACT ACTIVITY OF TAMARINDUS INDICA LINN. AGAINEST GLUCOSE-INDUCED CATARACTOGENISIS Dissertation submitted to The Tamil Nadu Dr. M. G. R. Medical University, Chennai in partial fulfillment of the award of degree of MASTER OF PHARMACY (PHARMACOLOGY) MARCH – 2009 COLLEGE OF PHARMACY SRI RAMAKRISHNA INSTITUTE OF PARAMEDICAL SCIENCES COIMBATORE – 641 044. 2 Results CERTIFICATE This is to certify that the dissertation entitled “IN VITRO ANTICATARACT ACTIVITY OF TAMARINDUS INDICA L. AGAINEST GLUCOSE-INDUCED CATARACTOGENISIS” being submitted to The Tamil Nadu Dr. M.G.R. Medical University, Chennai in partial fulfillment of the Master of Pharmacy programme in Pharmacology, carried out by Mr. SRIKANTH MERUGU in the Department of Pharmacology, College of Pharmacy, SRIPMS, Coimbatore, under my direct guidance and supervision to my fullest satisfaction. Mrs. M. UMA MAHESWARI, M.Pharm., (Ph.D.,) Assistant Professor, Dept. In-charge Department of Pharmacology, College of Pharmacy, SRIPMS, Place: Coimbatore Coimbatore –44. Date: 3 Results CERTIFICATE This is to certify that the dissertation entitled “IN VITRO ANTICATARACT ACTIVITY OF TAMARINDUS INDICA L. AGAINEST GLUCOSE-INDUCED CATARACTOGENISIS.” was carried out by Mr. SRIKANTH MERUGU, in the Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore, which is affiliated to The Tamil Nadu Dr.
    [Show full text]
  • Sample Chapter
    9 Endocrine system Diabetes mellitus 582 • Management 604 • Physiological principles of glucose and • Monitoring 628 insulin metabolism 582 Thyroid disease 630 • Epidemiology and classification 587 • Physiological principles 630 • Aetiology and pathogenesis 589 • Hypothyroidism 633 • Natural history 591 • Hyperthyroidism 637 • Clinical features 593 • References and further reading 643 • Complications 593 Endocrine control of physiological functions represents broadly targeted, slow acting but funda- mental means of homeostatic control, as opposed to the rapidly reacting nervous system. In endocrine disease there is usually either an excess or a lack of a systemic hormonal mediator, but the cause may be at one of a number of stages in the endocrine pathway. Thyroid disease and diabetes mellitus represent contrasting extremes of endocrine disease and its management. Diabetes is one of the most serious and probably the most common of multisystem diseases. Optimal control of diabetes requires day-to-day monitoring, and small variations in medication dose or patient activity can destabilize the condition. Therapy requires regular review and possible modification. Furthermore, long-term complications of diabetes cause considerable morbidity and mortality. Thyroid disease is a disorder of thyroid hormone production that has, compared to diabetes, equally profound overall effects on metabolic and physiological function. However, it causes few acute problems and has far fewer chronic complications. Moreover, management is much easier, requiring less intensive monitoring and few dose changes. Furthermore, control is rarely disturbed by short-term variations in patient behaviour. 582 Chapter 9 • Endocrine system Diabetes mellitus Diabetes mellitus is primarily a disorder of • Rapid: in certain tissues (e.g. muscle), insulin carbohydrate metabolism yet the metabolic facilitates the active transport of glucose and problems in properly treated diabetes are not amino acids across cell membranes, usually troublesome and are relatively easy to enhancing uptake from the blood.
    [Show full text]
  • Aldose Reductase Inhibitors for Diabetic Cataract: a Study of Disclosure Patterns in Patents and Peer Review Papers
    Ophthalmology Research: An International Journal 2(3): 137-149, 2014, Article no. OR.2014.002 SCIENCEDOMAIN international www.sciencedomain.org Aldose Reductase Inhibitors for Diabetic Cataract: A Study of Disclosure Patterns in Patents and Peer Review Papers H. A. M. Mucke1*, E. Mucke1 and P. M. Mucke1 1H. M. Pharma Consultancy, Enenkelstr. 28/32, A-1160 Wien, Austria. Authors’ contributions This work was carried out in collaboration between all authors. Author MHAM designed the study, performed the analysis, and drafted the manuscript. Authors EM and PMM performed data curation and iterative information retrieval. All authors read and approved the final manuscript. Received 29th September 2013 th Original Research Article Accepted 11 December 2013 Published 15th January 2014 ABSTRACT Aims: To investigate, for 13 aldose reductase inhibitors that had been in development for diabetic cataract, whether patent documents could provide earlier dissemination of knowledge to the ophthalmology community than peer review papers. Methodology: Searches for intellectual property disclosures were conducted in our internal database of ophthalmology patent documents, and were supplemented by online searches in the public Espacenet and Google Patents databases. Searches for peer review papers were performed in Pub Med and Google Scholar, and in our internal database of machine-readable ophthalmology publications. Results: For sorbinil, tolrestat, fidarestat and GP-1447 patent documents clearly preempted the peer review literature in terms of data-supported information on potential effectiveness in diabetic cataract, typically by 7-17 months. For alrestatin, zenarestat, zopolrestat, indomethacin, and quercitrin academic journals were clearly first to properly report this therapeutic utility, preempting the corresponding patents by 6 months to several years.
    [Show full text]
  • A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis And
    A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis and Glial Changes Induced by Diabetes in the Rat Veronica Asnaghi, Chiara Gerhardinger, Todd Hoehn, Abidemi Adeboje, and Mara Lorenzi We tested the hypothesis that the apoptosis of inner Mu¨ ller cells (the glia that share functions with astrocytes retina neurons and increased expression of glial fibril- in the inner retina but span the whole thickness of the lary acidic protein (GFAP) observed in the rat after a retina with their radial processes) (3). In diabetes, Mu¨ ller short duration of diabetes are mediated by polyol path- cells acquire prominent GFAP immunoreactivity through- way activity. Rats with 10 weeks of streptozotocin- out the extension of their processes (4,5), whereas astro- induced diabetes and GHb levels of 16 ؎ 2% (mean ؎ cytes progressively lose GFAP immunoreactivity (6) and SD) showed increased retinal levels of sorbitol and may also decrease in number (7); the levels of GFAP fructose, attenuation of GFAP immunostaining in astro- measured in the whole retina are increased (4,5). cytes, appearance of prominent GFAP expression in The retinal neuroglial abnormalities are observed before Mu¨ ller glial cells, and a fourfold increase in the number of apoptotic neurons when compared with nondiabetic the characteristic lesions of diabetic microangiopathy; rats. The cells undergoing apoptosis were immunoreac- they occur predominantly in the inner retina, where the tive for aldose reductase. Sorbinil, an inhibitor of al- capillaries also reside; and they involve cells that are dose reductase, prevented all abnormalities. Intensive topographically and functionally connected with vessels. insulin treatment also prevented most abnormalities, Understanding their mechanisms and consequences may despite reducing GHb only to 12 ؎ 1%.
    [Show full text]
  • Drug Therapy Targets for Diabetic Nephropathy: an Overview
    Int. J. Pharm. Sci. Rev. Res., 19(1), Mar – Apr 2013; nᵒ 24, 123-130 ISSN 0976 – 044X Review Article Drug Therapy Targets for Diabetic Nephropathy: An Overview Akash Jain1*, Jasmine Chaudhary1, Sunil Sharma2 and Vipin Saini1 1 M.M. College of Pharmacy, M.M. University, Mullana, India. 2Guru Jambeshwer University of Science and Technology, Hisar, India. *Corresponding author’s E-mail: [email protected] Accepted on: 30-01-2013; Finalized on: 28-02-2013. ABSTRACT Diabetic nephropathy is a leading cause of chronic kidney disease and end stage renal disease and accounts for significant morbidity and mortality in diabetic patients. Hyperglycemia may lead to end stage renal damage through both metabolic and non metabolic pathways. The non-enzymatic glycation of proteins with irreversible formation and deposition of reactive advanced glycation end products (AGE) have been noted to play a major role in the pathogenesis of diabetic nephropathy. Further, diabetic nephropathy is associated with hyperactivity of sorbitol aldose reductase pathway, hyperactivity of hexosamine biosynthetic pathway, activation of protein kinase C and MAPK and overexpression of growth factors and cytokines i.e. transforming growth factor-β, vascular endothelial growth factor, platelet-derived growth factor and insulin-like growth factor. Moreover, high glucose concentration in diabetes has been noted to induce oxidative and nitrosative stress, activate intracellular RAAS and release endothelin-1 and prostaglandins to deteriorate the function of kidney. In addition, up-regulation of transforming growth factor-β (TGF-β) and consequent overproduction of extracellular matrix molecules have been implicated in the progression of diabetic nephropathy. The present review study the various drug targets and drug therapy in diabetic nephropathy.
    [Show full text]